Rhenman & Partners Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-175,000	Closed	-$7.62M	–	100
2023 Q3	$7.62M	Buy	175,000 +35,000	+25%	+$1.25M	0.82%	41
2023 Q2	$5.06M	Sell	140,000 -75,000	-35%	-$3.09M	0.53%	56
2023 Q1	$7.89M	Sell	215,000 -85,000	-28%	-$3.82M	0.87%	37
2022 Q4	$13.6M	Buy	300,000 +102,933	+52%	+$6.66M	1.42%	29
2022 Q3	$13.3M	Buy	197,067 +7,067	+4%	+$523K	1.39%	29
2022 Q2	$12.8M	Buy	190,000 +40,200	+27%	+$2.56M	1.45%	27
2022 Q1	$12.3M	Sell	149,800 -200	-0.1%	-$20.5K	1.22%	33
2021 Q4	$22.2M	Hold	150,000	–	–	1.48%	24
2021 Q3	$26.5M	Sell	150,000 -15,000	-9%	-$2.41M	1.86%	15
2021 Q2	$26.7M	Buy	165,000 +15,000	+10%	+$2.41M	1.81%	14
2021 Q1	$25.7M	Buy	150,000 +50,000	+50%	+$9.9M	1.79%	19
2020 Q4	$22M	Sell	100,000 -14,311	-13%	-$3.09M	1.79%	18
2020 Q3	$19M	Buy	114,311 +14,311	+14%	+$1.96M	1.69%	22
2020 Q2	$11.4M	Sell	100,000 -30,000	-23%	-$2.91M	1.23%	34
2020 Q1	$9.99M	Buy	130,000 +5,000	+4%	+$448K	1.4%	30
2019 Q4	$16.1M	Buy	125,000 +25,000	+25%	+$2.41M	1.77%	17
2019 Q3	$7.79M	Sell	100,000 -82,008	-45%	-$7.7M	0.98%	42
2019 Q2	$18.7M	Buy	182,008 +54,915	+43%	+$4.28M	2.07%	15
2019 Q1	$9.32M	Buy	127,093 +42,093	+50%	+$2.86M	1.09%	37
2018 Q4	$3.61M	Buy	+85,000	New	+$3.39M	0.41%	63
2017 Q3	–	Sell	-50,000	Closed	-$183K	–	109
2017 Q2	$183K	Hold	50,000	–	–	0.03%	105
2017 Q1	$260K	Hold	50,000	–	–	0.04%	101
2016 Q4	$238K	Hold	50,000	–	–	0.05%	102
2016 Q3	$331K	Hold	50,000	–	–	0.05%	94
2016 Q2	$273K	Hold	50,000	–	–	0.05%	94
2016 Q1	$1.07M	Hold	50,000	–	–	0.21%	87
2015 Q4	$1.58M	Hold	50,000	–	–	0.24%	88
2015 Q3	$1.72M	Hold	50,000	–	–	0.27%	82
2015 Q2	$1.57M	Buy	50,000 +4,612	+10%	+$136K	0.19%	92
2015 Q1	$1.33M	Buy	+45,388	New	+$1.06M	0.22%	86

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Rhenman & Partners Asset Management's MRTX Position: Q4 2023 in Review

Rhenman & Partners Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 175,000 shares — an estimated $7.62M sold.

Rhenman & Partners Asset Management first reported a position in MRTX in Q1 2015 and held it in 30 quarters. The position peaked at $26.7M in Q2 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Rhenman & Partners Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Rhenman & Partners Asset Management sold 175,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $7.62M.
Rhenman & Partners Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2015 and held it in 30 quarters.
Rhenman & Partners Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $26.7M in Q2 2021.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.